Dihydrocodeine

Standard Drug Panel Inclusion

Dihydrocodeine is a natural or semi-synthetic opiate that is detected on standard 5-panel drug screens under the opiates channel. The standard opiate immunoassay targets morphine and codeine as primary analytes, and Dihydrocodeine or its metabolites will trigger a positive result due to structural similarity to the morphine backbone. Most workplace, clinical, and probation drug tests include opiate detection at a 2000 ng/mL or 300 ng/mL cutoff.

Urine Detection

Dihydrocodeine can be detected in urine for approximately 2 to 3 days after the last dose. The primary metabolic pathways involve glucuronidation, O-demethylation, and N-demethylation. Key urinary metabolites include glucuronide conjugates and, depending on the specific compound, morphine or hydromorphone as downstream metabolites. Hydration status, urinary pH, body mass, and metabolic rate all influence the exact detection window.

Blood and Saliva Detection

Dihydrocodeine is detectable in blood for approximately 6 to 24 hours after administration. Oral fluid (saliva) testing can detect Dihydrocodeine for approximately 24 to 48 hours post-dose. Blood and oral fluid testing are most commonly used in emergency medicine, pain management compliance monitoring, and roadside testing programs.

Hair Follicle Detection

Hair follicle testing can detect Dihydrocodeine for up to 90 days (approximately 1.5 inches of hair growth). Opiate incorporation into hair is well-characterized, and most commercial hair testing panels include the opiates category. A standard hair test screens for codeine, morphine, and 6-monoacetylmorphine; Dihydrocodeine or its metabolites will typically be captured under this panel.

Confirmatory Testing

Immunoassay screening results for opiates are confirmed using gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-tandem mass spectrometry (LC-MS/MS). These methods can distinguish between specific opiates, identifying Dihydrocodeine and its metabolites with high specificity. Confirmation testing eliminates false positives from poppy seed consumption or structural analogues.

Reagent Testing

Marquis reagent produces a purple to violet color with Dihydrocodeine, consistent with the morphine-class opiate reaction. Mecke reagent yields a deep blue-green to blue color. Mandelin reagent produces a grey-brown reaction. These reagent responses are characteristic of the opiate class and can help differentiate opiates from synthetic opioids, which may show different or no reactions.

It is strongly recommended that one use harm reduction practices when using this drug.

As with other opioids,moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal symptoms may occur if a person suddenly stops their usage.develops with prolonged and repeated use. The rate at which this occurs develops at different rates for different effects, with tolerance to the constipation-inducing effects developing particularly slowly for instance. This results in users having to administer increasingly large doses to achieve the same effects. After that,3 - 71 - 2 weeks to be back at baseline (in the absence of further consumption). Dihydrocodeine presents cross-tolerance with Cross-all other opioids, meaning that after the consumption of dihydrocodeine all opioids will have a reduced effect.

• Austria:** Dihydrocodeine is legal for medical use under the AMG (Arzneimittelgesetz Österreich) and illegal when sold or possessed without a prescription under the SMG (Suchtmittelgesetz Österreich).
• Australia:** Dihydrocodeine is a Schedule 3 medicine meaning it is available without prescription but is stored behind the counter at a pharmacy. Consultation with pharmacist is required for purchase. It is most commonly available as an oral liquid (Brand name Rikodeine) at a dose of 19mg/10mL in 100 or 200mL bottles.
• Germany:** Dihydrocodeine is a controlled substance under Anlage III of the BtMG. It can only be prescribed on a narcotic prescription form. There is an exception for preperations, containing up to 2,5% or 100mg dihydroco

Dihydrocodeine has a low toxicity relative to dose. As with all opiates, long-term effects can vary but can include diminished libido, apathy and memory loss. Some people may also have an allergic reaction to dihydrocodeine, such as the swelling of skin and rashes. It is also potentially lethal when mixed with depressants like alcohol or benzodiazepines.

It is strongly recommended that one use harm reduction practices when using this drug.

Tolerance and addiction potential

As with other opioids, the chronic use of dihydrocodeine can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal symptoms may occur if a person suddenly stops their usage.

Tolerance to many of the effects of dihydrocodeine develops with prolonged and repeated use. The rate at which this occurs develops at different rates for different effects, with tolerance to the constipation-inducing effects developing particularly slowly for instance. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the absence of further consumption). Dihydrocodeine presents cross-tolerance with all other opioids, meaning that after the consumption of dihydrocodeine all opioids will have a reduced effect.

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

• Alcohol - Both substances potentiate the ataxia and sedation caused by the other and can lead to unexpected loss of consciousness at high doses. Place affected patients in the recovery position to prevent vomit aspiration from excess. Memory blackouts are likely

• Stimulants - Stimulants increase respiration rate which allows for a higher dose of opiates than would otherwise be used. If the stimulant wears off first then the opiate may overcome the user and cause respiratory arrest.

• Benzodiazepines - Central nervous system and/or respiratory-depressant effects may be additively or synergistically present. The two substances potentiate each other strongly and unpredictably, very rapidly leading to unconsciousness. While unconscious, vomit aspiration is a risk if not placed in the recovery position blackouts/memory loss likely.

• DXM - Generally considered to be toxic. CNS depression, difficulty breathing, heart issues, and liver toxicity have been observed. Additionally if one takes DXM, their tolerance of opiates goes down slightly, thus causing additional synergistic effects.

• GHB/GBL - The two substances potentiate each other strongly and unpredictably, very rapidly leading to unconsciousness. While unconscious, vomit aspiration is a risk if not placed in the recovery position

• Ketamine - Both substances bring a risk of vomiting and unconsciousness. If the user falls unconscious while under the influence there is a severe risk of vomit aspiration if they are not placed in the recovery position.

• MAOIs - Coadministration of monoamine oxidase inhibitors (MAOIs) with certain opioids has been associated with rare reports of severe adverse reactions. There appear to be two types of interaction, an excitatory and a depressive one. Symptoms of the excitatory reaction may include agitation, headache, diaphoresis, hyperpyrexia, flushing, shivering, myoclonus, rigidity, tremor, diarrhea, hypertension, tachycardia, seizures, and coma. Death has occurred in some cases.

• MXE - MXE can potentiate the effects of opioids but also increases the risk of respiratory depression and organ toxicity.

• Nitrous - Both substances potentiate the ataxia and sedation caused by the other and can lead to unexpected loss of consciousness at high doses. While unconscious, vomit aspiration is a risk if not placed in the recovery position. Memory blackouts are common.

• PCP - PCP may reduce opioid tolerance, increasing the risk of overdose.

• Tramadol - Increased risk of seizures. Tramadol itself is known to induce seizures and it may have additive effects on seizure threshold with other opioids. Central nervous system- and/or respiratory-depressant effects may be additively or synergistically present.

• Grapefruit - While grapefruit is not psychoactive, it may affect the metabolism of certain opioids. Tramadol, oxycodone, and fentanyl are all primarily metabolized by the enzyme CYP3A4, which is potently inhibited by grapefruit juice. This may cause the drug to take longer to clear from the body. it may increase toxicity with repeated doses. Methadone may also be affected. Codeine and hydrocodone are metabolized by CYP2D6. People who are on medicines that inhibit CYP2D6, or that lack the enzyme due to a genetic mutation will not respond to codeine as it can not be metabolized into its active product: morphine.

• Austria:** Dihydrocodeine is legal for medical use under the AMG (Arzneimittelgesetz Österreich) and illegal when sold or possessed without a prescription under the SMG (Suchtmittelgesetz Österreich).

• Australia:** Dihydrocodeine is a Schedule 3 medicine meaning it is available without prescription but is stored behind the counter at a pharmacy. Consultation with pharmacist is required for purchase. It is most commonly available as an oral liquid (Brand name Rikodeine) at a dose of 19mg/10mL in 100 or 200mL bottles.

• Germany:** Dihydrocodeine is a controlled substance under Anlage III of the BtMG. It can only be prescribed on a narcotic prescription form. There is an exception for preperations, containing up to 2,5% or 100mg dihydrocodeine per unit, which can be prescripted on a regular prescription, if not prescripted to an alcohol or drug dependent person.

• Hong Kong:** In Hong Kong, dihydrocodeine is regulated under Schedule 1 of Hong Kong's Chapter 134 Dangerous Drugs Ordinance. It can only be used legally by health professionals and for university research purposes. A pharmacist can dispense Dihydrocodeine when furnished with a doctors prescription. Anyone who supplies the substance without a prescription can be fined $10000 (HKD). The penalty for trafficking or manufacturing the substance is a $5,000,000 (HKD) fine and life imprisonment. Possession of the substance for consumption, without a licence from the Department of Health, is illegal and carries a $1,000,000 (HKD) fine and/or 7 years imprisonment.

• Japan:** In Japan, dihydrocodeine is available without a prescription; used in cough medicines such as New Bron Solution-ACE. Dihydrocodeine is used as an antitussive in many products as a Dextromethorphan alternative. Medicines in Japan which contain dihydrocodeine are coupled with caffeine to offset the sedative effects and discourage recreational use. Cough medicines containing dihydrocodeine are controlled similarly to dextromethorphan in the United States, in that its sale is strictly limited by purchase quantity and is restricted to persons 20 and older for purchase.

• Russia:** Dihydrocodeine is a Schedule II controlled substance.

• Sweden: Dihydrocodeine is a prescription only medication.

• Switzerland: Dihydrocodeine is a controlled substance specifically named under Verzeichnis A. Medicinal use is permitted. Some preparations containing dihydrocodeine are included in Verzechnis C, while certain ones are excluded.

• United Kingdom:** In the United Kingdom, dihydrocodeine is a Class B drug; but, it is available over-the-counter in small amounts (less than 8 mg), when combined with paracetamol (see co-dydramol). Dihydrocodeine is listed in Schedule 5 of the Misuse of Drugs Regulations 2001 whereby it is exempt from prohibition on possession provided that it is in the form of a single preparation not being designed for injection and less than 100 mg (calculated as free base) or with a total concentration less than 2.5% (calculated as free base). Illegal possession of dihydrocodeine can result in up to 5 years in prison and/or a fine.

• United States:** In the USA, dihydrocodeine is a DEA Schedule II substance, although preparations containing small amounts of dihydrocodeine are classified as Schedule III or Schedule V, depending on the concentration of dihydrocodeine relative to other active constituents, such as paracetamol (acetaminophen). This scheduling is similar to the UK's. The DEA's ACSCN for dihydrocodeine free base and all salts is 9120. The 2013 annual aggregate manufacturing quota is 250 kilos.

• Responsible use

• Extraction of opioids from painkiller products

• Codeine

• Opioid

• Dihydrocodeine (Wikipedia)

• Dihydrocodeine (Erowid Vault)

• Dihydrocodeine (Isomer Design)

• Dihydrocodeine (DrugBank)

• Dihydrocodeine (Drugs.com)

• Schmidt, H., Vormfelde, S. V., Klinder, K., Gundert-Remy, U., Gleiter, C. H., Skopp, G., Aderjan, R. and Fuhr, U. (2002), Affinities of Dihydrocodeine and its Metabolites to Opioid Receptors. Pharmacology & Toxicology, 91: 57–63. https://doi.org/10.1034/j.1600-0773.2002.910203.x

• Koch T, Höllt V (2008). Role of receptor internalization in opioid tolerance and dependence. Pharmacol. Ther. 117 (2): 199–206. https://doi.org/10.1016/j.pharmthera.2007.10.003

• Pert, C. B., Pasternak, G., & Snyder, S. H. (1973). Opiate Agonists and Antagonists Discriminated by Receptor Binding in Brain. Science, 182 (4119), 1359-1361. https://doi.org/10.1126/science.182.4119.1359

• Friswell J, Phillips C, Holding J, Morgan CJ, Brandner B, Curran HV (2008). Acute effects of opioids on memory functions of healthy men and women. Psychopharmacology (Berl.). 198 (2): 243–50. https://doi.org/10.1007/s00213-008-1123-x.

• Stefano GB, Ptáček R, Kuželová H, Kream RM (2012). Endogenous morphine: up-to-date review (2011). Folia Biol. (Praha). 58 (2): 49–56. PMID 22578954.